🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tripping mice, ketamine analogues, and a vote of confidence from investors… MarcGunther⁩ covers ⁦Gilgamesh Pharma⁩ for ⁦⁦Lucid News⁩ lucid.news/gilgamesh-twea…

A new generation of pharmaceutical companies like Gilgamesh Pharma are emerging to treat #MentalIllness for a fraction of what it costs with better-known treatments. Read more about this revolution in medicine. on.wsj.com/3m77Awn

Thrilled to be on the 2023 list of top YC companies!

prnewswire.com/news-releases/… Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020 Single & multiple oral doses of GM-1020, a novel non-competitive NMDA channel blocker, were well-tolerated with no SAEs and confirmed target engagement via EEG.

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505 Single IV doses of GM-2505, a novel 5HT2A receptor agonist, demonstrated psychedelic effects lasting 60-90 min. and were well-tolerated with no SAEs prnewswire.com/news-releases/…

We're excited to share that Gilgamesh Pharma successfully completed its Phase 1 trial of GM-2505, which has the potential to improve outcomes for patients battling #mentalhealth disorders, such as alcohol use disorder, anxiety disorders, and OCD. prn.to/3R7eVIh

Excited to announce Gilgamesh's 1st peer-reviewed publication for GM-1020, our best in class oral ketamine analog. It is designed to have reduced dissociative/sedative properties which can potentially make it suitable for at-home use. nature.com/articles/s4138…

Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder prnewswire.com/news-releases/…

“What is the problem with ibogaine? It has cardiac toxicity,” “Volkow’s agency is already funding research into that question, awarding a $14M grant to Gilgamesh Pharma to develop an ibogaine analog … w/o the associated cardiovascular risk” STAT statnews.com/2024/03/21/ibo…

Gilgamesh Announces Initiation of Phase 2a Trial of GM-1020 (a novel oral NMDA receptor antagonist) in Major Depressive Disorder prnewswire.com/news-releases/…

ANNOUNCEMENT: We have partnered with @AbbVie through a collaboration and option-to-license agreement to advance the development of groundbreaking therapies for psychiatric disorders. Learn more prnewswire.com/news-releases/…

Breaking: AbbVie Inks Deal with Gilgamesh Pharmaceuticals AbbVie has become the latest large pharmaceutical company to dip its toes into psychedelic drug development as it announced what might be the most substantial foray of its kind this morning. psychedelicalpha.com/news/breaking-…

AbbVie goes deeper into neuroscience with collaboration worth as much as $2B - endpts.com/abbvie-goes-de…

Thrilled to be selected for the FiercePharma Fierce 15. fiercebiotech.com/special-report…

#Ibogaine analogs lack cardiac risk and disrupt #opioid use in animal models nature.com/articles/s4146…

New: We take a closer look at Gilgamesh's positive Phase 2a results of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder (MDD) & speak to company execs The results should provide a welcome catalyst for the field. psychedelicalpha.com/news/gilgamesh…

Today we announced positive topline data from our Phase 2a study of GM-2505 for Major Depressive Disorder. Read more: prnewswire.com/news-releases/…

Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ psychedelic drug candidate went into remission. fiercebiotech.com/biotech/gilgam…